Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida SPP. strains isolated from blood cultures;Kan kültürlerinden i̇zole edi̇len Candida SPP. suşlarinin anti̇fungal ilaçlara karşi duyarliliklarinin beli̇rlenmesi̇nde buyyon mi̇krodi̇lüsyon i̇le E-test yöntemleri̇ni̇n karşilaştirilmasi

Mikrobiyoloji Bulteni

Volumn 44, Issue 2, 2010, Pages 263-271

  Özcan, Sema Keçell ^a   Mutlu, Birsen ^a   Dündar, Devrim ^a   Wlllke, Ayşe ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Amphotericin B; Broth microdilution; Candida; Caspofungin; E test; Fluconazole; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; CANDIDA; CANDIDIASIS; COMPARATIVE STUDY; DRUG EFFECT; FUNGEMIA; HUMAN; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STANDARD;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 77952814873     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
2. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
3. rd ed. CLSI, Wayne, PA.
4. Chryssanthou E, Cuenca-Estrella M. Comparison of the antifungal susceptibility testing subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility of yeast species. J Clin Microbiol 2002; 40: 3841-4.
5. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother 2003; 47: 1647-51.
6. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German University Hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 2007; 59: 767-71.
7. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
8. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-231.
9. Epsinel Ingroff A. In vitro activity of new triazole (UK-109, 496) against opportunistic dimorphic and filamenteous fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36:198-202.
10. Heneger P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12: 2227-8.
11. Maertens J. Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis. Int J Antimicrob Agents 2006; 27: 457-67.
12. DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA. Invasive candidiasis treated in the intensive care unit: observation from a randomized clinical trial. J Crit Care 2007; 22: 237-44.
13. th ed. Mosby Co, St. Louis.
14. Koç AN, Gökahmetoǧlu S, Oǧuzkaya M. Comparison of E test with microdilution method in susceptibility testing of yeast isolates against four antifungals. Mycoses 2000; 43: 294-7.
15. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-26.
16. Epsinel-lngroff A. Mechanism of resistance to antifungal agents of yeasts and filamentous fungi. Rev Iberoam Micol 2008; 25: 101-6.
17. Quaiyumi S. Macro and microdilution methods, pp: 75-79. In: Schwalbe R, Steele-Moore L, Goodwin AC (eds), Antimicrobial Susceptibility Testing Protocols. 2007. CRS Press. New York.
18. Bakir M, Cerikcioǧlu N, Barton R, Yagci A. Epidemiology of candidemia in a Turkish tertiary care hospital. APMIS 2006; 114: 601-10.
19. Marchetti O, Bile J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
20. Zepelin MB, Kunz L, Rüchel R, et al. Epidemiology and antifungal suceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungemia on Germany from July 2004 to August 2005. J Antimicrob Chemother 2007; 60: 424-8.
21. Pfaller M, Diekema DJ, Jones RN, et al. International surveillance of bloodsteam infections due to Candida species: frequency of occurence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance programme. J Clin Microbiol 2001; 39: 3254-9.
22. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disc diffusion and Etest methods: report from the Artemis Global Antifungal Susceptibility Programme, 2001. J Clin Microbiol 2003; 41: 1440-6.
23. Cuenca-Estrella M, Rodriguez D, Almirante B, et al. In vitro susceptibilies of bloodstream isolates of Candida species to six antifungal agents: results from a population based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55: 194-9.
24. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Programme (2003). J Clin Microbiol 2006; 44: 1782-7.
25. Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of caspofungin compared to those of fluconazole and itraconazole against 3950 clinical isolates of Candida spp., including 157 fluconazole resistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-71.
26. Uzun O, Ankan S, Kocagöz S, Sancak B, Unal S. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University hospital and effect of time of reading. Diagn Microbiol Infect Dis 2000; 38: 101-7.
27. Mallie M, Bastide JM, Blanchard A, et al. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other fungal agents using Etest: results of a French multicentre study. Int J Antimicrob Agents 2005; 25: 321-8.
28. Rex JH, Nelson PW, Paetzinick WL, et al. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129-34.
29. Ankan S, Sancak B, Hascelik G. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Med Mycol 2005; 43: 171-8.